CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet.
2014;383(9930):1749-1761.
2. Zhao H, Wang Q, Luo C, Liu L, Xie W. Recompensation of decompensated
hepatitis B cirrhosis: Current status and challenges. BioMed Res Int.
2020;2020:9609731.
3. Wang W, Xiao P, Xu H, Niu J, Gao Y. Growing burden of alcoholic liver
disease in China: A review. World J Gastroenterol.
2019;25(12):1445-1456.
4. Rehm J, Shield KD. Global alcohol-attributable deaths from cancer,
liver cirrhosis, and injury in 2010. Alcohol Res. 2013;35(2):174-183.
5. EASL clinical practice guidelines for the management of patients with
decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
6. Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Clinical
course and mortality by etiology of liver cirrhosis in Sweden: A
population based, long-term follow-up study of 1317 patients. Aliment
Pharm Ther. 2019;49(11):1421-1430.
7. García-Martínez R, Simón-Talero M, Córdoba J. Prognostic assessment
in patients with hepatic encephalopathy. Dis Markers.
2011;31(3):171-179.
8. Fichet J, Mercier E, Genée O, et al. Prognosis and 1-year mortality
of intensive care unit patients with severe hepatic encephalopathy. J
Crit Care. 2009;24(3):364-370.
9. Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in
decompensated cirrhosis: Characterization and role in acute-on-chronic
liver failure. Hepatol. 2016;64(4):1249-1264.
10. Li Z, Wu H, Wei Y, et al. Impact of surveillance in chronic
hepatitis B patients on long-term outcomes after curative liver
resection for hepatocellular carcinoma. J Gastrointest Surg.
2020;24(9):1987-1995.
11. Huang H, Chen H, Hsu Y. Comparing the prognosis of patient with
alcohol and nonalcohol-associated cirrhosis with bacteremia. Alcohol
Alcohol. 2020;55(5):512-517.
12. Zhong HJ, Xiao P, Lin D, Zhou HM, He XX. Cirrhosis in wilson disease
is characterized by impaired hepatic synthesis, leukopenia and
thrombocytopenia. Int J Med Sci. 2020;17(10):1345-1350.
13. Moreau R, Elkrief L, Bureau C, et al. Effects of long-term
norfloxacin therapy in patients with advanced cirrhosis.
Gastroenterology. 2018;155(6):1816-1827.e1819.
14. Chen H, Zhang Y, Guo T, et al. Genetic variant rs72613567 of
HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han
population. Liver Int. 2020;40(9):2194-2202.
15. Hong Y, Sinn D, Gwak G, et al. Characteristics and outcomes of
chronic liver disease patients with acute deteriorated liver function by
severity of underlying liver disease. World J Gastroenterol.
2016;22(14):3785-3792.
16. Wang Z, Wu YF, Yue ZD, et al. Comparative study of indocyanine
green-R15, Child-Pugh score, and model for end-stage liver disease score
for prediction of hepatic encephalopathy after transjugular intrahepatic
portosystemic shunt. World J Gastroenterol. 2021;27(5):416-427.
17. Zhou C, Huang Y, Shu C, et al. Splenectomy before hepatectomy for
patients with hepatocellular carcinoma and hypersplenism: A
retrospective study. Medicine. 2021;100(4):e24326.
18. Valery P, McPhail S, Stuart K, et al. Changing prevalence of
aetiological factors and comorbidities among Australians hospitalised
for cirrhosis. Intern Med J. 2020.
19. Toshikuni N, Izumi A, Nishino K, et al. Comparison of outcomes
between patients with alcoholic cirrhosis and those with hepatitis C
virus-related cirrhosis. J Gastroenterol Hepatol. 2009;24(7):1276-1283.
20. Lv Y, Lau W, Li Y, et al. Hypersplenism: History and current status.
Exp Ther Med. 2016;12(4):2377-2382.
21. Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and
clinical significance of abnormal hematologic indices in compensated
cirrhosis. Clin Gastroenterol Hepatol. 2009;7(6):689-695.
22. Sugimoto S, Yamagishi Y, Ebinuma H, Kanai T. Spur cell anemia
associated with alcoholic cirrhosis. Intern Med. 2013;52(24):2831.
23. Zimmer V, Bittenbring J, Fries P, Lammert F. Severe mixed-type iron
overload in alcoholic cirrhosis related to advanced spur cell anemia.
Ann Hepatol. 2014;13(3):396-398.
24. Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence,
aetiology and related comorbidities of cirrhosis: a Swedish
population-based cohort study. BMC gastroenterology. 2020;20(1):84.
25. Lee Y, Kim C, Suk K, et al. Differences in cognitive function
between patients with viral and alcoholic compensated liver cirrhosis.
Metab Brain Dis. 2016;31(2):369-376.
26. Qureshi MO, Khokhar N, Shafqat F. Ammonia levels and the severity of
hepatic encephalopathy. J Coll Physicians Surg Pak. 2014;24(3):160-163.
27. Axley P, Ahmed Z, Arora S, et al. NASH is the most rapidly growing
etiology for acute-on-chronic liver failure-related hospitalization and
disease burden in the United States: A population-based study. Liver
Transpl. 2019;25(5):695-705.
28. Shalimar, Kedia S, Mahapatra SJ, et al. Severity and outcome of
acute-on-chronic liver failure is dependent on the etiology of acute
hepatic insults: Analysis of 368 patients. J Clin Gastroenterol.
2017;51(8):734-741.
TABLE 1 Patient
characteristics